This study emphasizes the contribution of ADCP through the treatment with -CD20 therapeutic mAbs, since clinically applied pharmaceuticals blocking ADCP (inhibitors for BTK, Pi3J or BCL2) were able to decrease ADCP in this model
This study emphasizes the contribution of ADCP through the treatment with -CD20 therapeutic mAbs, since clinically applied pharmaceuticals blocking ADCP (inhibitors for BTK, Pi3J or BCL2) were able to decrease ADCP in this model. strategies such as point mutations, altered…